{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:48:00Z","timestamp":1782992880380,"version":"3.54.5"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100020231","name":"FUCAP","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020231","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007509","name":"SEPAR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007509","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.arbres.2026.05.019","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:47:42Z","timestamp":1780616862000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Sarcoidosis"],"prefix":"10.1016","author":[{"given":"Juan Jose","family":"Zapata-Huizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Francesqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Veltkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Spagnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bonella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobo","family":"Sellares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2026.05.019_bib0445","first-page":"67","article-title":"Sarcoidosis: a state-of-the-art review","author":"Miedema","year":"2026","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.05.019_bib0450","doi-asserted-by":"crossref","first-page":"103993","DOI":"10.1016\/j.autrev.2026.103993","article-title":"Sarcoidosis: disease mechanisms, diagnostic pathway and treatment","volume":"25","author":"Miedema","year":"2026","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.arbres.2026.05.019_bib0455","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1055\/a-2768-2520","article-title":"Advanced pulmonary sarcoidosis","volume":"46","author":"Spagnolo","year":"2025","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2026.05.019_bib0460","first-page":"13","article-title":"Diagnostic delay and phenotypic differences in cardiac sarcoidosis: a descriptive study of diagnostic and follow-up clinical data","author":"Kullberg","year":"2026","journal-title":"Open Heart"},{"key":"10.1016\/j.arbres.2026.05.019_bib0465","article-title":"A paradigm shift in corticosteroid therapy for sarcoidosis: a World Association of Sarcoidosis and Other Granulomatous Disorders Position Paper, endorsed by the Americas Association of Sarcoidosis and Other Granulomatous Disorders","author":"Wells","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2026.05.019_bib0470","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jama.2022.1570","article-title":"Diagnosis and treatment of pulmonary sarcoidosis: a review","volume":"327","author":"Belperio","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.arbres.2026.05.019_bib0475","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00277-2024","article-title":"Inflammatory plasma protein levels are elevated years before sarcoidosis diagnosis: a nested case-control study in Sweden","volume":"64","author":"Arkema","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.05.019_bib0480","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0122-2025","article-title":"Scoping out sarcoidosis: the evolving role of bronchoscopy","volume":"35","author":"Ntiamoah","year":"2026","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.arbres.2026.05.019_bib0485","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/s41467-022-30615-x","article-title":"Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis","volume":"13","author":"Damsky","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.arbres.2026.05.019_bib0490","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40256-025-00781-6","article-title":"The role of sodium-glucose cotransporter 2 inhibitors in patients with sarcoid cardiomyopathy: a multicenter retrospective cohort study","volume":"26","author":"Mahmoud","year":"2026","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.arbres.2026.05.019_bib0495","first-page":"16","article-title":"Clinical updates of JAK inhibitors in cutaneous granulomatous diseases","author":"Gu","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.arbres.2026.05.019_bib0500","first-page":"40","article-title":"Efzofitimod: a novel anti-inflammatory agent for sarcoidosis","author":"Baughman","year":"2023","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.arbres.2026.05.019_bib0505","article-title":"Sarcoidosis: updates on therapeutic drug trials and novel treatment approaches","volume":"9","author":"Obi","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.arbres.2026.05.019_bib0510","article-title":"Janus kinase inhibitors in pulmonary and extrapulmonary sarcoidosis: a case series and systematic review of the literature","volume":"42","author":"Quaggetto","year":"2025","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.arbres.2026.05.019_bib0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.medcli.2025.107278","article-title":"Diagnostic value of angiotensin-converting enzyme levels for assessing organ involvement in sarcoidosis: a retrospective single-centre study","volume":"166","author":"L\u00f3pez-Mart\u00ednez","year":"2026","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.arbres.2026.05.019_bib0520","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4103\/lungindia.lungindia_461_25","article-title":"Predictive value of baseline serum angiotensin-converting enzyme levels for steroid response in sarcoidosis","volume":"43","author":"Mehta","year":"2026","journal-title":"Lung India"},{"key":"10.1016\/j.arbres.2026.05.019_bib0525","article-title":"Serum paraoxonase 1 as a marker of oxidative stress and pulmonary dysfunction in sarcoidosis: association with disease activity and prognostic potential","volume":"16","author":"Bozk\u00fcrk","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.arbres.2026.05.019_bib0530","first-page":"11","article-title":"Targeted proteomics in extracellular vesicles identifies biomarkers predictive for therapeutic response in sarcoidosis","author":"Kraaijvanger","year":"2025","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.arbres.2026.05.019_bib0535","unstructured":"ClinicalTrials.gov. Efficacy and safety study of OATD-01 in patients with active pulmonary sarcoidosis. NCT06205121. https:\/\/clinicaltrials.gov\/study\/NCT06205121 [accessed 3.4.26]."},{"key":"10.1016\/j.arbres.2026.05.019_bib0540","doi-asserted-by":"crossref","first-page":"15804","DOI":"10.1074\/jbc.272.25.15804","article-title":"Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate","volume":"272","author":"Smith","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.arbres.2026.05.019_bib0545","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1055\/a-2741-2030","article-title":"Biomarkers in sarcoidosis: from traditional markers to precision medicine","volume":"46","author":"Pascual","year":"2025","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2026.05.019_bib0550","doi-asserted-by":"crossref","first-page":"102709","DOI":"10.1016\/j.coi.2025.102709","article-title":"From X-rays to advanced imaging modalities in pulmonary sarcoidosis","volume":"98","author":"Ledda","year":"2026","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.arbres.2026.05.019_bib0555","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S2213-2600(23)00267-9","article-title":"High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study","volume":"12","author":"Desai","year":"2024","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2026.05.019_bib0560","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1007\/s10278-024-01377-3","article-title":"Radiomics and artificial intelligence in pulmonary fibrosis","volume":"38","author":"Chantzi","year":"2025","journal-title":"J Imaging Inform Med"},{"key":"10.1016\/j.arbres.2026.05.019_bib0565","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s11547-025-02067-y","article-title":"Unlocking the potential of radiomics in identifying fibrosing and inflammatory patterns in interstitial lung disease","volume":"130","author":"Colligiani","year":"2025","journal-title":"Radiol Med"},{"key":"10.1016\/j.arbres.2026.05.019_bib0570","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/j.sult.2026.01.002","article-title":"Radiomics for differentiating autoimmune-related interstitial lung disease from idiopathic pulmonary fibrosis: a narrative review","volume":"47","author":"Varela Betancourt","year":"2026","journal-title":"Semin Ultrasound CT MR"},{"key":"10.1016\/j.arbres.2026.05.019_bib0575","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.chest.2025.02.017","article-title":"Deciphering the role of fluorodeoxyglucose-positron emission tomography\/CT imaging in the management of sarcoidosis","volume":"168","author":"Donnelly","year":"2025","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2026.05.019_bib0580","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5603\/nmr.104702","article-title":"Utility of [18F]FDG PET\/CT in sarcoidosis management: a retrospective case series","volume":"28","author":"Zekri","year":"2025","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"10.1016\/j.arbres.2026.05.019_bib0585","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/RLU.0000000000006212","article-title":"Prognostic implications of volume-based quantitative 18F-FDG PET\/CT biomarkers in pulmonary sarcoidosis","volume":"51","author":"Shao","year":"2026","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.arbres.2026.05.019_bib0590","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13550-026-01380-5","article-title":"Optimizing PET\/CT protocols: is 60-min [18F]F-FDG uptake sufficient for cardiac sarcoidosis?","volume":"16","author":"Metzger","year":"2026","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.arbres.2026.05.019_bib0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2026.134181","article-title":"Prognostic value of 18F-fluorodeoxyglucose positron emission tomography 1 month after initiation of prednisolone therapy in patients with cardiac sarcoidosis","volume":"448","author":"Tamura","year":"2026","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.arbres.2026.05.019_bib0600","doi-asserted-by":"crossref","DOI":"10.1097\/MNM.0000000000002113","article-title":"Diagnostic performance of 68Ga-DOTANOC PET\/computed tomography in cardiac sarcoidosis: comparison with 18F-fluorodeoxyglucose PET\/computed tomography and cardiac magnetic resonance","author":"Solanki","year":"2026","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.arbres.2026.05.019_bib0605","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s41824-025-00263-7","article-title":"Emerging PET radiotracers in cardiovascular, neuroinflammation, lung, and rheumatological diseases: a narrative review","volume":"9","author":"Albano","year":"2025","journal-title":"EJNMMI Rep"},{"key":"10.1016\/j.arbres.2026.05.019_bib0610","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12931-025-03455-8","article-title":"Proof-of-concept PET imaging of pulmonary sarcoidosis using VAP-1-targeted radiotracer [68Ga]Ga-DOTA-Siglec-9","volume":"27","author":"Dadson","year":"2025","journal-title":"Respir Res"},{"key":"10.1016\/j.arbres.2026.05.019_bib0615","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/1754-9485.70061","article-title":"Complementary roles of cardiac MRI and FDG-PET\/CT in the evaluation of cardiac sarcoidosis: insights from a single-centre retrospective study","volume":"70","author":"Drew","year":"2026","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.arbres.2026.05.019_bib0620","first-page":"14","article-title":"Prognostic value of atrial phasic dysfunction by CMR feature tracking for new-onset atrial fibrillation in patients with cardiac sarcoidosis","author":"Nita","year":"2026","journal-title":"Biomedicines"},{"key":"10.1016\/j.arbres.2026.05.019_bib0625","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3390\/jcm15020650","article-title":"Unmasking early cardiac fibrosis in sarcoidosis: the role of plasma aldosterone and cardiac MRI","volume":"15","author":"Giallafos","year":"2026","journal-title":"J Clin Med"},{"key":"10.1016\/j.arbres.2026.05.019_bib0630","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1093\/eurheartj\/ehaf338","article-title":"Prediction of ventricular arrhythmic outcomes in suspected cardiac sarcoidosis: a comparison of cardiovascular magnetic resonance phenotyping vs societal recommendations for implantable cardioverter-defibrillator placement","volume":"46","author":"Mathijssen","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arbres.2026.05.019_bib0635","article-title":"EBUS-guided transbronchial mediastinal cryobiopsy for diagnosing nonmetastatic lymphadenopathy: a randomized controlled trial","volume":"7","author":"Deng","year":"2026","journal-title":"Med (N Y)"},{"key":"10.1016\/j.arbres.2026.05.019_bib0640","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/eus.0000000000000147","article-title":"Endobronchial ultrasound-guided transbronchial mediastinal cryobiopsy versus transbronchial needle aspiration for diagnosing sarcoidosis: a randomized controlled trial","volume":"14","author":"Deng","year":"2025","journal-title":"Endosc Ultrasound"},{"key":"10.1016\/j.arbres.2026.05.019_bib0645","first-page":"12","article-title":"Additional diagnostic potential of transbronchial lung cryobiopsy in bronchoscopic assessment of sarcoidosis and chronic beryllium disease: a retrospective analysis of 321 patients","author":"Terschluse","year":"2025","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.arbres.2026.05.019_bib0650","first-page":"17","article-title":"Bronchoscopic diagnosis of pulmonary sarcoidosis using endobronchial ultrasonography-guided transbronchial needle aspiration and transbronchial lung cryobiopsy: a safe and high-yield dual approach","author":"Ota","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.arbres.2026.05.019_bib0655","article-title":"Emerging diagnostic techniques in sarcoidosis: a path forward","volume":"99","author":"De Crem","year":"2026","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.arbres.2026.05.019_bib0660","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.chest.2021.10.025","article-title":"Diagnostic performance of electronic nose technology in sarcoidosis","volume":"161","author":"van der Sar","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2026.05.019_bib0665","doi-asserted-by":"crossref","DOI":"10.1093\/ajrccm\/aamaf085","article-title":"International validation of electronic nose technology as a diagnostic tool for fibrotic interstitial lung diseases","author":"Formsma","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2026.05.019_bib0670","article-title":"Incidence of new comorbidities after steroid use in patients with sarcoidosis: an international cross-sectional survey","author":"Harper","year":"2025","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2026.05.019_bib0675","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00198-2023","article-title":"High-dose (40mg) versus low-dose (20mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial)","volume":"62","author":"Dhooria","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.05.019_bib0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2025.102679","article-title":"Treating sarcoidosis: when less is more","volume":"97","author":"Logan","year":"2025","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.arbres.2026.05.019_bib0685","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.05.019_bib0690","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1056\/NEJMoa2501443","article-title":"First-line treatment of pulmonary sarcoidosis with prednisone or methotrexate","volume":"393","author":"Kahlmann","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2026.05.019_bib0695","doi-asserted-by":"crossref","first-page":"6828","DOI":"10.3390\/jcm14196828","article-title":"Immunosuppressive therapies in pulmonary sarcoidosis: a practical, evidence-based review","volume":"14","author":"Dhanani","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.arbres.2026.05.019_bib0700","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1055\/a-2746-4508","article-title":"Treatment of sarcoidosis over the next decade","volume":"46","author":"Cattran","year":"2025","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2026.05.019_bib0705","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/thorax-2025-223014","article-title":"Systematic review and meta-analysis of the efficacy of biologic and targeted synthetic therapies in sarcoidosis","volume":"80","author":"Bechman","year":"2025","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2026.05.019_bib0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103247","article-title":"The immunopathogenesis of sarcoidosis","volume":"149","author":"Miedema","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.arbres.2026.05.019_bib0715","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis","volume":"379","author":"Damsky","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2026.05.019_bib0720","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jaad.2019.05.098","article-title":"Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare","volume":"82","author":"Damsky","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.arbres.2026.05.019_bib0725","doi-asserted-by":"crossref","first-page":"4237","DOI":"10.1038\/s41598-017-04109-6","article-title":"Identification of JAK-STAT signaling involvement in sarcoidosis severity via a novel microRNA-regulated peripheral blood mononuclear cell gene signature","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.arbres.2026.05.019_bib0730","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00408-021-00436-8","article-title":"Tofacitinib as a steroid-sparing therapy in pulmonary sarcoidosis: an open-label prospective proof-of-concept study","volume":"199","author":"Friedman","year":"2021","journal-title":"Lung"},{"key":"10.1016\/j.arbres.2026.05.019_bib0735","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaad.2020.10.016","article-title":"Tofacitinib for cutaneous and pulmonary sarcoidosis: a case series","volume":"84","author":"Kerkemeyer","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.arbres.2026.05.019_bib0740","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.chest.2022.10.037","article-title":"Efzofitimod for the treatment of pulmonary sarcoidosis","volume":"163","author":"Culver","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2026.05.019_bib0745","unstructured":"aTyr Pharma. aTyr Pharma announces topline results from phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis. https:\/\/investors.atyrpharma.com\/news-releases\/news-release-details\/atyr-pharma-announces-topline-results-phase-3-efzo-fittm-study [accessed 10.1.26]."},{"key":"10.1016\/j.arbres.2026.05.019_bib0750","series-title":"Presented at: European Respiratory Society Congress","article-title":"Late breaking abstract: EFZO-FIT, the largest ever interventional trial in pulmonary sarcoidosis","author":"Culver","year":"2025"},{"key":"10.1016\/j.arbres.2026.05.019_bib0755","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.cyto.2012.12.016","article-title":"Circulating cytokines in sarcoidosis: phenotype-specific alterations for fibrotic and nonfibrotic pulmonary disease","volume":"61","author":"Patterson","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.arbres.2026.05.019_bib0760","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1440-1843.1998.tb00130.x","article-title":"Secretion of GM-CSF by inflammatory cells in the lung of patients with sarcoidosis","volume":"3","author":"Itoh","year":"1998","journal-title":"Respirology"},{"key":"10.1016\/j.arbres.2026.05.019_bib0765","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1136\/thx.48.12.1230","article-title":"Correlation of GM-CSF mRNA in bronchoalveolar fluid with indices of clinical activity in sarcoidosis","volume":"48","author":"Itoh","year":"1993","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2026.05.019_bib0770","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01874-2025","article-title":"Safety and efficacy of namilumab for the treatment of chronic pulmonary sarcoidosis (RESOLVE-Lung): a randomized, double-blind, multicenter, phase 2 study","author":"Van Den Blink","year":"2026","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2026.05.019_bib0775","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.hrtlng.2025.10.001","article-title":"Repurposing sodium-glucose cotransporter 2 inhibitors in sarcoidosis: a potential strategy for reducing mortality","volume":"75","author":"Alam","year":"2026","journal-title":"Heart Lung"},{"key":"10.1016\/j.arbres.2026.05.019_bib0780","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.3390\/ph18111729","article-title":"PDE-4 inhibition in sarcoidosis patients: a retrospective single-center analysis of 51 patients","volume":"18","author":"Feineis","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.arbres.2026.05.019_bib0785","first-page":"6","article-title":"Efficacy and safety of mTOR inhibition in cutaneous sarcoidosis: a single-centre trial","author":"Redl","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.arbres.2026.05.019_bib0790","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2026.05.019_bib0795","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases: subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2026.05.019_bib0800","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2026.05.019_bib0805","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa2503643","article-title":"Nerandomilast in patients with progressive pulmonary fibrosis","volume":"392","author":"Maher","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2026.05.019_bib0810","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11882-025-01222-9","article-title":"Sarcoidosis in the genomic era: from genetic drivers to tailored therapies","volume":"25","author":"Rivera","year":"2025","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.arbres.2026.05.019_bib0815","first-page":"17","article-title":"Cardiac sarcoidosis: the role of steroid therapy in managing myocardial inflammation and arrhythmic risks","author":"Bhimani","year":"2025","journal-title":"World J Cardiol"},{"key":"10.1016\/j.arbres.2026.05.019_bib0820","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/jce.70204","article-title":"Propensity-matched 5-year cardiac resynchronization therapy outcomes in sarcoidosis with heart failure","volume":"37","author":"Yeo","year":"2026","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.arbres.2026.05.019_bib0825","article-title":"Predicting sudden cardiac death in patients with sarcoidosis using a multimodal artificial intelligence model","author":"Lai","year":"2025","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.arbres.2026.05.019_bib0830","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.pulmoe.2023.12.002","article-title":"Comparison of cryobiopsy and forceps biopsy for the diagnosis of mediastinal lesions: a randomised clinical trial","volume":"30","author":"Cheng","year":"2024","journal-title":"Pulmonology"},{"key":"10.1016\/j.arbres.2026.05.019_bib0835","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S2213-2600(22)00392-7","article-title":"Transbronchial needle aspiration combined with cryobiopsy in the diagnosis of mediastinal diseases: a multicentre, open-label, randomised trial","volume":"11","author":"Fan","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2026.05.019_bib0840","first-page":"149","article-title":"Diagnosis and management of cardiac sarcoidosis: a scientific statement from the American Heart Association","author":"Cheng","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.arbres.2026.05.019_bib0845","first-page":"307","article-title":"Prognostic value of cardiac MRI and FDG PET in cardiac sarcoidosis: a systematic review and meta-analysis","author":"Aitken","year":"2023","journal-title":"Radiology"},{"key":"10.1016\/j.arbres.2026.05.019_bib0850","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s10554-024-03191-y","article-title":"Prognostic role of late gadolinium-enhanced MRI in confirmed and suspected cardiac sarcoidosis: meta-analysis","volume":"40","author":"Sekii","year":"2024","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1016\/j.arbres.2026.05.019_bib0855","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1093\/eurheartj\/ehae356","article-title":"Management of cardiac sarcoidosis","volume":"45","author":"Sharma","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arbres.2026.05.019_bib0860","article-title":"A review of sarcoidosis etiology, diagnosis and treatment","volume":"12","author":"Waly","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.arbres.2026.05.019_bib0865","first-page":"326","article-title":"New updates in sarcoidosis research: defining and renewing the quest","author":"Bonham","year":"2024","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.arbres.2026.05.019_bib0870","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMe2504736","article-title":"Methotrexate as initial therapy for symptomatic pulmonary sarcoidosis?","volume":"393","author":"Baughman","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2026.05.019_bib0875","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s43556-025-00244-z","article-title":"Sarcoidosis: molecular mechanisms and therapeutic strategies","volume":"6","author":"Xu","year":"2025","journal-title":"Mol Biomed"},{"key":"10.1016\/j.arbres.2026.05.019_bib0880","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.pulmoe.2024.03.002","article-title":"Complete response to mTOR inhibitor following JAK inhibitor failure in severe pulmonary sarcoidosis","volume":"30","author":"Hindr\u00e9","year":"2024","journal-title":"Pulmonology"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289626002115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289626002115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:37:27Z","timestamp":1782992247000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289626002115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":88,"alternative-id":["S0300289626002115"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2026.05.019","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in Sarcoidosis","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2026.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}